Palliative and supportive therapy of esophageal cancer

被引:0
作者
Lorenzen, S. [1 ]
Siveke, J. T. [2 ]
van Oorschot, B. [3 ]
机构
[1] Tech Univ Munich, Med Klin 3, Abt Hamatol & Onkol, Klinikum Rechts Isar, D-81675 Munich, Germany
[2] Tech Univ Munich, Med Klin 3, Klinikum Rechts Isar, D-81675 Munich, Germany
[3] Univ Klinikum Wurzburg, Interdisziplinares Zentrum Palliat Med, Klin & Poliklin Strahlentherapie, Wurzburg, Germany
来源
ONKOLOGE | 2014年 / 20卷 / 12期
关键词
Esophageal carcinoma; Palliative therapy; Dysphagia; Stent; Radiochemotherapy; SQUAMOUS-CELL CARCINOMA; RANDOMIZED PHASE-III; ARBEITSGEMEINSCHAFT INTERNISTISCHE ONKOLOGIE; SINGLE-DOSE BRACHYTHERAPY; ESOPHAGOGASTRIC JUNCTION; STENT PLACEMENT; GASTROESOPHAGEAL JUNCTION; 1ST-LINE TREATMENT; GASTRIC-CANCER; OPEN-LABEL;
D O I
10.1007/s00761-014-2761-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The prognosis for patients with advanced esophageal cancer is poor and palliative therapy for these patients necessitates a broad spectrum of different measures to relieve symptoms. However, the increasing knowledge of tumor biology of adenocarcinoma and squamous cell cancer of the esophagus may facilitate improved treatment options. Local treatment modalities include endoscopic stenting and hemostasis, radiotherapy and very rarely palliative resection. Systemic chemotherapy usually combines two or three cytotoxic drugs with the aim to improve prognosis and possibly to alleviate symptoms. In patients with unresectable or metastatic esophageal cancer, multimodal treatment (i.e. radiotherapy, chemotherapy, combined radiochemotherapy, palliative and supportive care) should be individualized and conducted within all subspecialties (tumor board conferences). The choice of the procedure is based on the symptoms, the tumor situation, the patients' general status and patient preferences. If possible an individual, interdisciplinary treatment concept should be designed for each patient and modified according to the course of the disease.
引用
收藏
页码:1217 / 1221
页数:5
相关论文
共 29 条
[1]   Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase III trial [J].
Amdal, Cecilie Delphin ;
Jacobsen, Anne-Birgitte ;
Sandstad, Berit ;
Warloe, Trond ;
Bjordal, Kristin .
RADIOTHERAPY AND ONCOLOGY, 2013, 107 (03) :428-433
[2]   Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: A systematic review [J].
Amdal, Cecilie Delphin ;
Jacobsen, Anne-Birgitte ;
Guren, Marianne Gronlie ;
Bjordal, Kristin .
ACTA ONCOLOGICA, 2013, 52 (04) :679-690
[3]  
[Anonymous], J CLIN ONCOL S3
[4]   Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].
Bang, Yung-Jue ;
Van Cutsem, Eric ;
Feyereislova, Andrea ;
Chung, Hyun C. ;
Shen, Lin ;
Sawaki, Akira ;
Lordick, Florian ;
Ohtsu, Atsushi ;
Omuro, Yasushi ;
Satoh, Taroh ;
Aprile, Giuseppe ;
Kulikov, Evgeny ;
Hill, Julie ;
Lehle, Michaela ;
Ruschoff, Josef ;
Kang, Yoon-Koo .
LANCET, 2010, 376 (9742) :687-697
[5]   ANTITUMOR EFFECTS OF DOXORUBICIN IN COMBINATION WITH ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODIES [J].
BASELGA, J ;
NORTON, L ;
MASUI, H ;
PANDIELLA, A ;
COPLAN, K ;
MILLER, WH ;
MENDELSOHN, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (16) :1327-1333
[6]   Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial [J].
Bergquist, H ;
Wenger, U ;
Johnsson, E ;
Nyman, J ;
Ejnell, H ;
Hammerlid, E ;
Lundell, L ;
Ruth, M .
DISEASES OF THE ESOPHAGUS, 2005, 18 (03) :131-139
[7]   Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer [J].
Bleiberg, H ;
Conroy, T ;
Paillot, B ;
Lacave, AJ ;
Blijham, G ;
Jacob, JH ;
Bedenne, L ;
Namer, M ;
DeBesi, P ;
Gay, F ;
Collette, L ;
Sahmoud, T .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (08) :1216-1220
[8]   Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin [J].
Burmeister B.H. ;
Walpole E.T. ;
Burmeister E.A. ;
Thomas J. ;
Thomson D.B. ;
Harvey J.A. ;
Smithers B.M. ;
Gotley D.C. .
International Journal of Clinical Oncology, 2005, 10 (4) :256-261
[9]   The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma-025EFindividual patient data from 1775 patients in four randomised controlled trials [J].
Chau, I. ;
Norman, A. R. ;
Cunningham, D. ;
Oates, J. ;
Hawkins, R. ;
Iveson, T. ;
Nicolson, M. ;
Harper, P. ;
Seymour, M. ;
Hickish, T. .
ANNALS OF ONCOLOGY, 2009, 20 (05) :885-891
[10]   Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction [J].
Dank, M. ;
Zaluski, J. ;
Barone, C. ;
Valvere, V. ;
Yalcin, S. ;
Peschel, C. ;
Wenczl, M. ;
Goker, E. ;
Cisar, L. ;
Wang, K. ;
Bugat, R. .
ANNALS OF ONCOLOGY, 2008, 19 (08) :1450-1457